openPR Logo
Press release

Cabozantinib- API Insight, 2018

04-19-2019 03:37 PM CET | Health & Medicine

Press release from: Cabozantinib -Pharma Proff

Cabozantinib, sold under the brand name of Cabometyx and Cometriq, is used for the treatment of medullary thyroid cancer and a second line treatment for renal cell carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET.

Download the sample report @ https://www.pharmaproff.com/request-sample/1164

Discovered and developed by Exelixis Inc., its side-effects include increased liver enzymes, diarrhea, low calcium, mouth sores, decreased appetite and nausea.

In advanced renal cell carcinoma, which is a form of kidney cancer, Cabozantinib is used in those patients who have been previously treated with a type of cancer medicine called ‘vascular endothelial growth factor (VEGF) inhibitor.

Get the detailed analysis @ https://www.pharmaproff.com/report/cabozantinib

It is also used in patients who have not undergone previous treatment and whose cancer is at moderate or high risk. In hepatocellular carcinoma, which is a form of liver cancer, it is used in patients who have already been treated with the cancer medicine such as Sorafenib. It is currently marketed in Europe and the U.S.

Make enquiry before purchase @ https://www.pharmaproff.com/enquiry/1164

This report provides details of the drug and the API manufacturers across the 7 major markets which includes U.S, EU5, and Japan. It includes the overview, mechanism, regulatory milestones, strategic developments, the historical and forecasted sales. The pipeline analysis of the drug by phase which would include the product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology and others.

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Cabozantinib- API Insight, 2018 here

News-ID: 1711171 • Views: 523

More Releases for VEGF

Current Market Scenario of Global Anti-vascular Endothelial Growth Factor (Anti- …
This report also researches and evaluates the impact of Covid-19 outbreak on the Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.). Global Anti-vascular Endothelial Growth Factor (Anti-VEGF) Drugs Market Overview: The latest report on the
Global VEGF/VEGFR Inhibitor Drugs Industry Research Analysis by 2020- 2025
This report also researches and evaluates the impact of Covid-19 outbreak on the VEGF/VEGFR Inhibitor Drugs industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on VEGF/VEGFR Inhibitor Drugs and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.). GLOBAL INFO RESEARCH has lately published a new report titled, *Global and Japan VEGF/VEGFR Inhibitor Drugs Market 2020 by Company, Type and Application, Forecast to
Vascular Endothelial Growth Factor (VEGF) Antibodies Market By 2026 Genentech, N …
Vascular Endothelial Growth Factor (VEGF) is a signal protein that helps in the formation of new blood vessels through a process known as angiogenesis. Vascular endothelial growth factor is a part of several pathological processes and researches are often carried out for the development of novel therapies using these factors for diseases such as cancer. Normal functions of vascular endothelial growth factor includes embryonic development, formation of new blood vessels,
Vascular Endothelial Growth Factor (VEGF) Antibodies Market Trends, Outlook, and …
Vascular Endothelial Growth Factor (VEGF) is a signal protein that helps in the formation of new blood vessels through a process known as angiogenesis. Vascular endothelial growth factor is a part of several pathological processes and researches are often carried out for the development of novel therapies using these factors for diseases such as cancer. Normal functions of vascular endothelial growth factor includes embryonic development, formation of new blood vessels,
Market Insights: Anti-VEGF Drugs to Remain Preferred for Treatment of Proliferat …
Researchmoz added Most up-to-date research on "Proliferative Diabetic Retinopathy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2026" to its huge collection of research reports. Proliferative diabetic retinopathy prevails as leading cause of blindness across industrialized countries worldwide. Although remarkable advancements have been made in the diagnosis and treatment of the disease, several imperative management questions as well as treatment deficiencies continue to persist unanswered. The
Global Ophthalmic Therapeutics-Drug Market By Type | Antiallergy, Anti-VEGF agen …
Researchmoz added Most up-to-date research on "Global Ophthalmic Therapeutics-Drug Market By Type | Antiallergy, Anti-VEGF agents, Anti-inflammatory and Antiglaucoma" to its huge collection of research reports. This report studies the global Ophthalmic Therapeutics/Drug market, analyzes and researches the Ophthalmic Therapeutics/Drug development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like Novartis AG Allergan Santen Pharmaceutical Co., Ltd. Pfizer Inc. Merck &